Hong Kong Stock Market Movement | Heptagon Pharmaceuticals-B(02142) surged over 8% in early trading. The new generation CTLA-4 antibody goes global, with total sales possibly exceeding $1.2 billion.

2026-02-23 05:28:26

Abstract generation in progress

Tongji Finance APP has learned that HeBot Medical-B (02142) rose over 8% in early trading. As of the time of writing, it increased by 7.92%, trading at HKD 13.21, with a turnover of HKD 21.7947 million.

On the news front, on February 23, HeBot Medical announced that it will grant global rights outside Greater China for the next-generation CTLA-4 antibody HBM4003 to Solstice Oncology. The latter will pay an upfront consideration of over $105 million, including a $50 million initial payment, a $5 million recent payment, and company equity valued at over $50 million.

In addition, HeBot Medical will also receive milestone payments of up to $1.1 billion, as well as tiered sales royalties. Public information shows that Solstice Oncology is a clinical-stage biotech company founded by multiple leading venture capital firms. This cooperation is based on a NewCo model.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes